...
首页> 外文期刊>Science Immunology >BNT162b2 vaccination induces durable SARS-CoV-2–specific T cells with a stem cell memory phenotype
【24h】

BNT162b2 vaccination induces durable SARS-CoV-2–specific T cells with a stem cell memory phenotype

机译:BNT162B2疫苗接种可诱导使用干细胞记忆表型诱导耐用的SARS-COV-2特异性T细胞

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is effective in preventing hospitalization from severe COVID-19. However, multiple reports of breakthrough infections and of waning antibody titers have raised concerns on the durability of the vaccine, and current vaccination strategies now propose administration of a third dose. Here, we monitored T cell responses to the Spike protein of SARS-CoV-2 in 71 healthy donors vaccinated with two doses of the Pfizer-BioNTech mRNA vaccine (BNT162b2) for up to 6 months after vaccination. We found that vaccination induced the development of a sustained anti-viral CD4+ and CD8+ T cell response. These cells appeared before the development of high antibody titers, displayed markersof immunological maturity and stem cell memory, survived the physiological contraction of the immune response, and persisted for at least 6 months. Collectively, these data show that vaccination with BNT162b2 elicits an immunologically competent and long-lived SARS-CoV-2–specific T cell population.
机译:针对严重急性呼吸道综合征2(SARS-COV-2)的疫苗接种可有效防止严重的COVID住院治疗。然而,关于突破感染和减弱抗体滴度的多个报道提高了人们对疫苗持久性的担忧,而当前的疫苗接种策略现在提出了第三剂的施用。在这里,我们监测了T细胞对SARS-COV-2的尖峰蛋白的反应,其中71名健康供体在接种疫苗后最多6个月,在71名健康供体中,用两剂辉瑞甲基苯乙酸mRNA mRNA疫苗(BNT162B2)接种了6个月。我们发现疫苗接种诱导持续的抗病毒CD4+和CD8+ T细胞反应的发展。这些细胞出现在高抗体滴度的发展之前,显示了免疫成熟度和干细胞记忆的标记,在免疫反应的生理收缩中幸存下来,并持续至少6个月。总的来说,这些数据表明,使用BNT162B2的疫苗接种引起了免疫学胜任和长期寿命的SARS-COV-2特异性T细胞群。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号